NanoBone®
Rapid Osteogenesis

FOR IMMEDIATE RELEASE

Contact:
Paul Byerley
Chief Executive Officer
+1 320.259.4321
pbyerley@artossinc.com

Artoss Announces FDA Clearance to Market of NanoBone SBX Putty

Clearance Expands NanoBone role in U.S. Orthopaedic Surgery

St. Cloud, MN, November 8, 2016/ -- Artoss, Inc. (St. Cloud, MN), a medical device company that is pioneering the use of advanced bone graft substitutes to treat multiple orthopaedic indications, announced that, on October 26, 2016, Artoss GmbH received notice from the U.S. Food & Drug Administration that NanoBone® SBX Putty has been cleared to market as 510(k) K161351.

Walter Gerike, Managing Director of Artoss GmbH said, "Nanotechnology is the key technology for the 21st century and Artoss is harnessing this potential for orthopaedic surgery. In NanoBone SBX Putty, we have a product that combines Applied NanoBiology™ for bone repair with perfect handling for the surgeon." NanoBone synthetic bone graft products have been used in Europe for ten years, approaching 100,000 clinical cases across all indications.

James J. Cassidy, Ph.D., Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, stated, "NanoBone technology has been in great demand by U.S. surgeons since we launched NanoBone Granules in 2015. NanoBone SBX Putty offers the same clinical performance in an easier to use presentation. We look forward to introducing this product in a variety of sizes to the U.S. market in the coming weeks."

NanoBone has consistent and cost-effective outcomes in bone grafting in multiple orthopaedic indications. NanoBone achieves these outcomes with no preparation required, excellent handling for surgeons, creation of an osteogenic matrix within 14 days, and clinical and radiographic healing in as little as 8 weeks. The dramatic growth in NanoBone procedures further secures its growing market position as a leader in the bone repair space. There is growing acceptance by surgeons that not all bone graft substitutes are the same, given the rapid osteogenic matrix formation of NanoBone within 14 days.

###

About NanoBone

NanoBone was first cleared by the Food and Drug Administration (FDA) in 2015 after having been successfully used in Europe for ten years. Clinical publications have identified

bone graft substitutes as an increasingly important component of many orthopaedic procedures. Consistent healing in orthopaedic procedures is a significant unmet clinical need and one where NanoBone may provide an effective option.

NanoBone is a commercially available product in the U.S. intended to fill bony voids or gaps of the skeletal system (i.e., extremities, posterolateral spine and pelvis). These osseous defects are surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. NanoBone® SBX Putty resorbs and is replaced with bone during the healing process.

###

About Artoss, Inc.

Artoss, Inc. (St. Cloud, MN) is a medical device company that is a leading distributor of bioidentical bone graft substitutes to treat multiple orthopaedic indications and is dedicated to the development of tools and products for effectively treating a variety of orthopaedic conditions requiring surgical intervention. The company markets, NanoBone Bone Graft Substitute, which is gives clinical outcomes comparable to autograft with less postoperative pain and complications. Artoss, Inc. has an experienced management team with extensive experience in orthopaedic medical devices.